Peripheral Neuropathy and Low Dose Cisplatin
- 1 December 1988
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 11 (6) , 660-662
- https://doi.org/10.1097/00000421-198812000-00014
Abstract
Five of 55 patients with metastatic carcinomas or unresectable primary carcinomas developed a peripheral neuropathy with "low dose" cisplatin therapy, consisting of 20 mg/m2 weekly. The neuropathy was primarily sensory, consisting of painful parasthesias and numbness in a "stocking glove" distribution. The cumulative dose at which neuropathy developed varied from 100 to 640 mg/m2. The symptoms and signs of neurologic dysfunction were minimally reversible despite discontinuation of the drug. Despite lower dose delivery of cisplatin, significant debilitating neurologic toxicity may occur.This publication has 5 references indexed in Scilit:
- Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studiesCancer, 1984
- NERVE-CONDUCTION STUDIES IN PATIENTS TREATED WITH CIS-DIAMMINEDICHLOROPLATINUM(II) - A PRELIMINARY-REPORT1980
- PHASE I STUDY OF CIS-DIAMMINEDICHLOROPLATINUM(II) ADMINISTERED AS A CONSTANT 5-DAY INFUSION1980
- Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatmentCancer, 1979
- PERIPHERAL NEUROPATHY AS A COMPLICATION OF CIS-DICHLORODIAMMINEPLATINUM(II) TREATMENT - CASE-REPORT1978